Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.

Novartis AG NVS, a Swiss pharma giant, is scheduled to report second-quarter 2025 results on July 17. The Zacks Consensus ...

FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer ...

FRANKFURT (Reuters) -Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an ...

FDA approves Novartis' Pluvicto for advanced prostate cancer patients who have received ARPI therapy.

Novartis said Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. The Swiss pharmaceutical company on Monday said Pluvicto showed ...

Pluvicto is the only PSMA-targeted agent approved for PSMA-positive mCRPC and is the first targeted RLT to demonstrate a clinical benefit for patients with PSMA-positive mHSPC 1. Novartis is ...

Novartis announced that the US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for patients with prostate-specific membrane antigen (PSMA)-positive ...

Sales of Novartis AG’s closely-watched prostate cancer drug Pluvicto disappointed in the latest quarter, taking the shine off a raised profit forecast from the Swiss pharma company.

Novartis (NVS) announced that the Food and Drug Administration approved Pluvicto for patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer who ...